Managing diabetes in diabetic patients with COVID: where do we start from?
Acta Diabetol
; 58(11): 1441-1450, 2021 Nov.
Article
in English
| MEDLINE | ID: covidwho-1281282
ABSTRACT
AIMS:
COVID-19 has and still is sweeping away the national health systems worldwide. In this review, we sought to determine the evidence base proofs on the antidiabetic treatment capable to reduce the risk of COVID-19-related mortality.METHODS:
We have performed a systematic search of published articles using PubMed, and EMBASE from March 2020 to March 31st, 2021. We excluded editorials, commentary, letters to the editor, reviews, and studies that did not have mortality as an outcome. For metformin and insulin only, we performed a meta-analysis using Cochrane RevMan 5.2.RESULTS:
Among antidiabetic drugs, metformin was the only drug associated with a reduced risk of mortality. Conversely, insulin appears associated with an increased risk. The other classes of drugs were neutral.CONCLUSIONS:
The totality of articles reports retrospective data strongly affected by "channeling bias" so that most of the existing results on each class of drugs are driven by the phenotype of patients likely to receive that specific drug by prescription.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Diabetes Mellitus
/
COVID-19
Type of study:
Observational study
/
Prognostic study
/
Reviews
/
Systematic review/Meta Analysis
Limits:
Humans
Language:
English
Journal:
Acta Diabetol
Journal subject:
Endocrinology
Year:
2021
Document Type:
Article
Affiliation country:
S00592-021-01739-1
Similar
MEDLINE
...
LILACS
LIS